GAIN THERAPEUTICS INC (GANX)
US36269B1052 - Common Stock
GANX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. GANX has a bad profitability rating. Also its financial health evaluation is rather negative. GANX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GANX had negative earnings in the past year.
GANX had a negative operating cash flow in the past year.
In the past 5 years GANX always reported negative net income.
In the past 5 years GANX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -119.68%, GANX is not doing good in the industry: 82.71% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -177.07%, GANX is doing worse than 68.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -119.68% | ||
| ROE | -177.07% | ||
| ROIC | N/A |
ROA(3y)-76.09%
ROA(5y)-119.48%
ROE(3y)-103.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GANX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GANX has been increased compared to 1 year ago.
Compared to 1 year ago, GANX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.73, we must say that GANX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.73, GANX is in line with its industry, outperforming 46.92% of the companies in the same industry.
GANX has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
GANX has a Debt to Equity ratio (0.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.73 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
GANX has a Current Ratio of 3.59. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a Current ratio of 3.59. This is comparable to the rest of the industry: GANX outperforms 40.75% of its industry peers.
GANX has a Quick Ratio of 3.59. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.59, GANX is in line with its industry, outperforming 41.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.59 | ||
| Quick Ratio | 3.59 |
3. Growth
3.1 Past
The earnings per share for GANX have decreased strongly by -20.27% in the last year.
Looking at the last year, GANX shows a very negative growth in Revenue. The Revenue has decreased by -60.00% in the last year.
The Revenue has been growing by 22.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q7.69%
Revenue 1Y (TTM)-60%
Revenue growth 3Y22.52%
Revenue growth 5Y22.5%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 15.46% on average over the next years. This is quite good.
Based on estimates for the next years, GANX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y31.81%
EPS Next 2Y16.21%
EPS Next 3Y1.41%
EPS Next 5Y15.46%
Revenue Next Year267.41%
Revenue Next 2Y13.05%
Revenue Next 3Y-28.9%
Revenue Next 5Y-14.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.21%
EPS Next 3Y1.41%
5. Dividend
5.1 Amount
GANX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GAIN THERAPEUTICS INC
NASDAQ:GANX (4/26/2024, 7:00:00 PM)
After market: 3.08 +0.05 (+1.65%)3.03
-0.04 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap49.15M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -119.68% | ||
| ROE | -177.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.59 | ||
| Quick Ratio | 3.59 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-20.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60%
Revenue growth 3Y22.52%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y